Prognostic factors and benefit populations of ovarian function suppression in premenopausal HR+/HER2+ early‐stage breast cancer patients who received trastuzumab: Evidence from a real‐world study with long‐term follow‐up

Prognostic factors and benefit populations of ovarian function suppression in premenopausal HR+/HER2+ early‐stage breast cancer patients who received trastuzumab: Evidence from a real‐world study with long‐term follow‐up

Abstract Background Hormone receptor‐positive (HR+)/human epidermal growth factor receptor 2‐positive (HER2+) breast cancer exhibits considerable heterogeneity, and it is of great interest whether patients with premenopausal HR+/HER2+ breast cancer treated with trastuzumab can benefit from ovarian f...

Full description

Bibliographic Details
Main Authors: Jie Ju, Song‐Lin Gao, Jia‐Yu Wang, Die Sang, Yi‐Kun Kang, Xue Wang, Jian Yue, You Shuai, Yi‐Xin Qi, Peng Yuan
Format: Article
Language:English
Published: Wiley 2024-02-01
Series:Thoracic Cancer
Subjects:
breast cancer
hormone receptor
human epidermal growth factor receptor 2
ovarian function suppression
trastuzumab
Online Access:https://doi.org/10.1111/1759-7714.15211

Similar Items

Similar Items